Insider Trading March 5, 2026

FMC Director Michael F. Barry Buys $249,938 in Stock as Share Price Sits Near Year Low

Director makes a roughly $250,000 purchase amid steep share price decline; company also reports mixed Q4 results and a credit downgrade

By Hana Yamamoto FMC
FMC Director Michael F. Barry Buys $249,938 in Stock as Share Price Sits Near Year Low
FMC

FMC Corporation director Michael F. Barry acquired 18,072 shares of FMC common stock on March 4, 2026, paying a weighted average of $13.83 per share for a transaction totaling about $249,938. The purchase, carried out through attorney-in-fact Sara Ponessa, raises Barry’s direct holdings to 19,634 shares. The insider buy comes as FMC shares have plunged 64% over the past year to $14.39. Recent corporate developments include Q4 2025 earnings that met EPS expectations but missed revenue, a Moody's downgrade to Ba1 from Baa3 amid patent expirations and greater generic competition, Barry’s election to the board, and a declared quarterly dividend of $0.08 per share.

Key Points

  • Director Michael F. Barry purchased 18,072 FMC shares on March 4, 2026, at a weighted average price of $13.83, totaling roughly $249,938.
  • FMC’s stock has declined 64% over the past year and is trading at $14.39; InvestingPro analysis cited in filings indicates the stock is below its Fair Value and appears on a Most Undervalued list.
  • Corporate developments include Q4 2025 EPS of $1.20 that met expectations, revenue of $1.08 billion below the $1.15 billion expected, a Moody’s downgrade to Ba1 from Baa3 due to patent expirations and competitive pressures, the election of Barry to the board, and a quarterly dividend of $0.08 payable April 16, 2026.

Summary

FMC Corporation director Michael F. Barry reported a material insider purchase on a Form 4 filing with the Securities and Exchange Commission. On March 4, 2026, Barry purchased 18,072 shares of FMC common stock at a weighted average price of $13.83 per share, for a total consideration of approximately $249,938. The acquisition was executed by an attorney-in-fact, Sara Ponessa. After the transaction, Barry directly holds 19,634 FMC shares.


Insider purchase details

The Form 4 filing indicates the trade price range was between $13.77 and $13.86, with the weighted average recorded as $13.83. The insider buying occurred while the company’s stock has been under significant pressure - the share price is down 64% over the last 12 months and is trading at $14.39.


Financial results and valuation signals

FMC reported fourth-quarter 2025 earnings in which diluted earnings per share matched expectations at $1.20. Revenue for the quarter came in at $1.08 billion, below the $1.15 billion that had been anticipated. Separately, InvestingPro’s analysis cited in the filing describes FMC as trading below its Fair Value and lists the company among its Most Undervalued stocks.


Credit rating action and competitive pressures

Moody’s has downgraded FMC’s senior unsecured ratings to Ba1 from Baa3, a move characterized in the filing as a shift to junk status. The downgrade is attributed to patent expirations and rising competition in the generic crop protection chemicals market, factors Moody’s indicated negatively affect the company’s credit profile.


Board role and shareholder payout

The company has announced the election of Michael F. Barry to its board of directors. Barry will serve on the Audit and the Compensation and Human Capital committees. Additionally, FMC declared a quarterly cash dividend of $0.08 per share, payable April 16, 2026, to shareholders of record as of March 31, 2026.


Contextual note

The Form 4 filing and the company disclosures present a mix of signals: a director purchase concurrent with a sharp year-over-year decline in the stock, a beat/miss pattern in quarterly results, a credit-rating downgrade tied to industry-specific pressures, and a modest dividend payment schedule.

Risks

  • Credit risk tied to the Moody’s downgrade to Ba1 from Baa3, driven by patent expirations and increased competition in the generic crop protection chemicals market - impacting corporate creditworthiness and financing conditions in the chemicals and agriculture inputs sectors.
  • Revenue shortfall risk evidenced by Q4 2025 revenue of $1.08 billion versus the expected $1.15 billion, which could reflect demand or pricing pressures in crop protection chemicals and related agricultural markets.
  • Market risk related to the company’s 64% decline in share price over the past year, which may influence investor confidence and liquidity for shareholders.

More from Insider Trading

Peapack-Gladstone Director Sells Small Stake as Company Moves to Redeem Debt and Grant Executive RSUs Mar 23, 2026 Progressive Accounting Chief Disposes $55K in Stock as Shares Trade Near Yearly Low Mar 23, 2026 Old Second Bancorp Vice Chairman Disposes $429K in Shares; Ownership Stakes and Recent Results Also Detailed Mar 23, 2026 Vicor Chairman Disposes $7.9 Million in Stock; Transaction Executed Under 10b5-1 Plan Mar 23, 2026 Nutex Health President Buys $23,706 in Stock as Q4 Revenue Slumps 41.1% Mar 23, 2026